IDH1 Antibody

說明書

中文名稱：

IDH1兔多克隆抗體
貨號：

CSB-PA010989GA01HU
規(guī)格：

￥3,900
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

O75874
基因名：

IDH1
別名：

Cytosolic NADP isocitrate dehydrogenase antibody; Cytosolic NADP-isocitrate dehydrogenase antibody; Epididymis luminal protein 216 antibody; Epididymis secretory protein Li 26 antibody; HEL-216 antibody; HEL-S-26 antibody; ICDH antibody; IDCD antibody; IDH antibody; IDH1 antibody; IDHC_HUMAN antibody; IDP antibody; IDPC antibody; Isocitrate dehydrogenase (NADP(+)) 1 cytosolic antibody; Isocitrate dehydrogenase [NADP] cytoplasmic antibody; Isocitrate dehydrogenase 1 (NADP+) soluble antibody; NADP dependent isocitrate dehydrogenase cytosolic antibody; NADP dependent isocitrate dehydrogenase peroxisomal antibody; NADP(+)-specific ICDH antibody; Oxalosuccinate decarboxylase antibody; PICD antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Human IDH1
免疫原種屬：

Homo sapiens (Human)
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB,IHC
Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

基因功能參考文獻：
1. mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma PMID: 29871612
2. High IDH1 expression is associated with Malignant Transformation of Benign Prostatic Epithelium. PMID: 29331887
3. Low IDH1 expression level might be an adverse prognostic biomarker for clinical outcomes of ccRCC patients, and two nomograms with IDH1 are potential effective prognostic models for ccRCC. PMID: 30153799
4. In this review, we summarize current knowledge regarding the function of normal and mutated IDH(socitrate dehydrogenases 1 and 2 ), explain the possible mechanisms through which these mutations might drive malignant transformation of progenitor cells in the central nervous system, and provide a comprehensive review of potential treatment strategies for IDH-mutated malignancies, focusing on gliomas. PMID: 30194083
5. In patients with supratentorial diffuse gliomas, IDH1-R132H mutations are associated with a more severe phenotype of postoperative epilepsy. These findings support further research into IDH mutations, and the potential for an antiepileptic therapeutic effect of their inhibitors, in patients with glioma-associated epilepsy. PMID: 29172136
6. Ollier disease is thought to be caused by a post-zygotic mutation of IDH resulting in a mosaicism and IDH mutation is a common genetic event in tumorigenesis. PMID: 30159860
7. Identification of driver and subclonal mutations in ASXL1 and IDH1/IDH2 genes in an Argentine series of patients with myelofibrosis. PMID: 29761621
8. an overview of the biological and clinical implications of IDH1 and IDH2 mutations in acute myeloid leukemia (review). PMID: 29543066
9. genetic association studies in population in Czech Republic: Data suggest that mutations in IDH1 and IDH2 are associated with AML (acute myeloid leukemia); IDH1/2-based monitoring of MRD (minimal residual disease) appears to have prognostic value for residual disease in AML patients. PMID: 30176240
10. There was significant prognostic difference among the 4 glioma subtypes. Combined IDH and TERT gene mutation analysis may be useful for prognostic subgrouping. Notably, IDH1 wild-type cases can be further subdivided into TERT(+ ) or (-) subgroups with significant prognostic difference. PMID: 30220117
11. Generation of 2-hydroxyglutarate by mutated IDH1/2 leads to the activation of mTOR by inhibiting KDM4A. PMID: 27624942
12. IDH1 mutation is associated with glioma progression. PMID: 29016871
13. promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate dehydrogenase (IDH) mutation, is reported. PMID: 29396294
14. IDH1 and B7H3 cannot be used as independent prognostic factors, co-expression of IDH1 and B7H3 significantly correlated with the prognosis of CRC patients and may serve as a combined predictive marker. Thus, the correlation between IDH1 and B7H3 has been proven in vivo and in vitro. PMID: 29871819
15. Co-administration of VOR did not increase the overall response rate (P = 0.84) or overall survival (OS; P = 0.32). Specifically, no benefit was identified in either de novo or relapsed AML. Mutations in the genes CDKN2A (P = 0.0001), IDH1 (P = 0.004), and TP53 (P = 0.003) were associated with reduced OS PMID: 28765326
16. IDH mutant gliomas are less aggressive, occur in younger patients, are easier to resect, more chemosensitive, and associated with longer survival when compared with IDH wild-type tumors, regardless of histologic grade. PMID: 29369751
17. IDH1 gene mutation is exclusive in supratentorial Brain Tumors and more frequent in secondary ones, with a greater survival trend and better progression free survival in patients who carry it. PMID: 28948065
18. we elucidated the antitumor effect of curcumol on MGC-803 cells and the involved mechanisms related to the induction of apoptosis, the increase of ROS, the decrease of MMP and the downregulation of IDH1. PMID: 29039582
19. Study provides the first evidence that ID1 conferred oxaliplatin resistance in hepatocellular carcinoma proliferation by activating the pentose phosphate pathway. PMID: 29169374
20. No correlation between IDH1/2 mutation status and sensitivity for NAMPT inhibitors was observed. Strikingly, higher methylation of the NAPRT promoter was observed in high-grade versus low-grade chondrosarcomas. In conclusion, this study identified NAMPT as a potential target for treatment of chondrosarcoma PMID: 28860121
21. IDH1 mutation, karyotype risk and the revised International Prognostic Scoring System risk category were independent inferior prognostic factors. PMID: 28873367
22. Results highlight that non-canonical IDH mutations are relatively common in grade II and III gliomas: it is therefore important to analyze exon 4 of both IDH1 and IDH2 in these tumors. They also demonstrate that all IDH mutations, including the non-canonical ones are clonally distributed, a finding consistent with their driver role in gliomagenesis. PMID: 28748342
23. IDH1 mutation promotes gliomagenesis not by altering cell growth but by arresting differentiation of Neural Stem Cells, which become locked in a self-renewing and brain-invasive state. PMID: 29091765
24. Data demonstrate that IDH1 mutation reduces the malignant progression of glioma by causing a less aggressive phenotype of GSCs which are involved in the Wnt/betacatenin signaling. PMID: 29115585
25. Results demonstrated that wild-type IDH1 is over-expressed in lung adenocarcinoma which probably promoted tumor progression via increasing cancer stem cells survival. PMID: 29537891
26. Low expression of IDH1 is associated with osteosarcoma. PMID: 28534992
27. Patients with grade II gliomas showed a higher rate of IDH1 and IDH2 mutations and seizures than patients with grade III and IV gliomas--{REVIEW} PMID: 29288860
28. current meta-analysis identified that IDH1 mutation was correlated to a higher preoperative seizure incidence in low-grade gliomas PMID: 29414139
29. inhibition of Bcl-xL induces significantly more apoptosis in IDH1-mutated cells than in wild-type IDH1 cells. PMID: 29057925
30. The rare occurrence of IDH1 mutant high-grade thalamic gliomas strongly suggested that the high-grade thalamic glioma is another distinct tumor entity as compared to the high-grade superficial gliomas. PMID: 28869450
31. Our findings indicate that IDH1WT glioma have a typical Warburg phenotype whereas in IDH1MUT glioma the TCA cycle, rather than glycolytic lactate production, is the predominant metabolic pathway. Our data further suggest that the TCA in IDH1MUT glioma is driven by lactate and glutamate anaplerosis to facilitate production of alpha-KG, and ultimately D-2-HG. PMID: 28467784
32. The aim of this study is to determine the prevalence of IDH mutations and EGFR amplifications in the population of the northeast region of Morocco and then to compare the results with other studies. PMID: 28785587
33. this epigenetic antagonism precedes malignant transformation and can be observed in preleukemic LSK cells from Idh2(R140Q) or Dnmt3a(R882H) single-mutant and Idh2(R140Q)/Dnmt3a(R882H) double-mutant mice. IDH/DNMT3A double-mutant acute myeloid leukemia (AML)manifested upregulation of a RAS signaling signature and displayed unique sensitivity to MEK inhibition ex vivo as compared with AMLs with either single mutation. PMID: 28408400
34. IDH1(R314C) lacks isocitrate-to-alpha-ketoglutarate conversion activity due to reduced affinity for NADP(+), and differs from the IDH1(R132) mutants in that it does not produce D-2-hydroxyglutarate. PMID: 27460417
35. Findings demonstrated that miR-148a promotes glioma cell invasion and tumorigenesis by downregulating GADD45A. Findings provide novel insights into how GADD45A is downregulated by miR-148a in IDH1R132H glioma PMID: 28445981
36. Glioblastoma multiforme HIF1-alpha and serum VEGF levels were found to be significantly increased in IDH1-mutated tumor tissues.Mutated IDH1 may contribute to carcinogenesis via induction of HIF-1 alpha pathway in primary glioblastoma multiforme. PMID: 28667042
37. IDH1 mutation is associated with 1p19q co-deletion diffuse glioma. PMID: 28340142
38. DNA mutational analysis in IDH1 in acute myeloid leukemia. PMID: 27071442
39. Authors conclude that PROX1 is a new prognostic biomarker for 1p19q non-codeleted high-grade astrocytomas that have progressed from pre-existing low-grade tumors and harbor IDH1 mutations. PMID: 27626492
40. In primary human acute myeloid leukemia samples, the 2-hydroxyglutarate levels observed in samples with mutant IDH1 or IDH2 status were higher than those observed in samples without an enzyme mutation, similar to what was observed in the original study (Figure 5C; Ward et al., 2010). PMID: 28653623
41. Results present a unique phenotype of isocitrate dehydrogenase-mutation primary de novo glioblastomas arising from insular cortex region, the molecular backgrounds of which are similar to secondary glioblastomas. PMID: 28116838
42. These findings suggest that IDH1 upregulation represents a common metabolic adaptation by glioblastoma to support macromolecular synthesis, aggressive growth, and therapy resistance. PMID: 28564604
43. Patients with low IDH1-R132H expression had a poor overall survival. Our data indicate that IDH1-R132H expression could be used as a predictive marker of prognosis for patients with gastrointestinal cancer. PMID: 27655638
44. ATRX deficiency was mutually exclusive with LOH. Conversely, ATRX-proficient tumours immunoreactive for R132H-mutant isocitrate dehydrogenase 1 (IDH1) showed a high rate (85%) of LOH. PMID: 26016385
45. FZD7 and IDH1 were assessed by immunohistochemistry in tissue microarrays. PMID: 27409829
46. TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms. PMID: 28218607
47. our finding that the expression of MCT1 and MCT4 is reduced in mutant IDH1 gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 tumors and has important implications for our understanding of these tumors and their treatment PMID: 27144334
48. IDH1/2 mutations induce a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase inhibitors PMID: 28148839
49. To confirm this result, we analyzed survival data from 142 LGGs from TCGA with IDH1/IDH2 mutations and no 1p19q codeletion. Despite the high rate of censured data, we found that CNLOH 17p, including the TP53 locus, was associated with better outcome (OR = 0.27; p = .026) PMID: 27401888
50. Results suggest that to better treat gliomas, isocitrate dehydrogenase (NADP(+)) 1 (IDH-1) mutation status should be included when determining WHO2007 grade in glioma patients. PMID: 27120786
顯示更多

收起更多
相關(guān)疾病：

Glioma (GLM)
亞細胞定位：

Cytoplasm, cytosol. Peroxisome.
蛋白家族：

Isocitrate and isopropylmalate dehydrogenases family
數(shù)據(jù)庫鏈接：

HGNC: 5382

OMIM: 137800

KEGG: hsa:3417

STRING: 9606.ENSP00000260985

UniGene: Hs.593422

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human